Skip to main content

DNA vaccines: An evolving approach to the treatment of allergic disorders

Buy Article:

$39.50 plus tax (Refund Policy)

Abstract:

Immunotherapy with protein allergens is effective in modulating the immune response and reducing symptoms in patients with allergic rhinitis and asthma. Unfortunately, the dose of allergen that can be administered to allergic asthmatic patients, who might most benefit from this form of therapy, is frequently limited because of reduced FEV1 and safety concerns. Therefore, alternative strategies to identify ways to minimize the allergenicity of immunotherapy while improving the effectiveness are currently being investigated in animal models of asthma and in human subjects with allergic rhinitis. Several DNA-based methods of immunization (CpG DNA, CpG DNA conjugated to a protein allergen, and plasmid DNA) have shown promise in animal models of asthma, and some of these DNA-based therapies have entered phase I/II clinical trials. Furthermore, ongoing large-scale phase III clinical trials will be able to determine whether any of these DNA-based therapies are safe and effective to use in subjects with allergic rhinitis and asthma.

Document Type: Review Article

Publication date: 2005-05-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • www.AJRA.com
  • www.AllergyandRhinology.com
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more